Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients

Tiziano Barbui,Alessandra Carobbio

DOI: https://doi.org/10.1038/s41408-024-00987-y

IF: 9.812

2024-01-24

Blood Cancer Journal

Abstract:Blood Cancer Journal, Published online: 23 January 2024; doi:10.1038/s41408-024-00987-y Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients

oncology,hematology

What problem does this paper attempt to address?

Development and validation of a model for the early prediction of progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: a multicentre retrospective study

Danhong Xiang,Xiudi Yang,Honglan Qian,Li Zhang,Yanxia Han,Yongcheng Sun,Ying Lu,Yu Chen,Dan Cao,Meiwei Hu,Lifeng Wang,Qinli Tang,Dijiong Wu,Guoyan Tian,Hongyan Tong,Jie Jin,Jian Huang

DOI: https://doi.org/10.1016/j.eclinm.2023.102378

IF: 15.1

2023-12-14

EClinicalMedicine

Abstract:Background: Essential thrombocythemia (ET), a myeloproliferative neoplasm (MPN), has a substantial risk of evolving into post-essential thrombocythemia myelofibrosis (post-ET MF). This study aims to establish a prediction nomogram for early prediction of post-ET MF in ET patients. Methods: The training cohort comprised 558 patients from 8 haematology centres between January 1, 2010, and May 1, 2023, while the external validation cohort consisted of 165 patients from 6 additional haematology centres between January 1, 2010, and May 1, 2023. Univariable and multivariable Cox regression analysis was performed to identified independent risk factors and establish a nomogram to predict the post-ET MF free survival. Both bias-corrected area under the curve (AUC), calibration curves and concordance index (C-index) were employed to assess the predictive accuracy of the nomogram. Findings: Multivariate Cox regression demonstrated that elevated red blood cell distribution width (RDW), elevated levels of lactate dehydrogenase (LDH) and the level of haemoglobin (Hb), a history of smoking and the presence of splenomegaly were independent risk factors for post-ET MF. The C-index displayed of the training and validation cohorts were 0.877 and 0.853. The 5 years, 10 years AUC values in training and external validation cohorts were 0.948, 0.769 and 0.978, 0.804 respectively. Bias-corrected curve is close to the ideal curve and revealed a strong consistency between actual observation and prediction. Interpretation: We developed a nomogram capable of predicting the post-ET MF free survival probability at 5 years and 10 years in ET patients. This tool helps doctors identify patients who need close monitoring and appropriate counselling. Funding: This research was funded by the Key R&D Program of Zhejiang (No. 2022C03137); the Public Technology Application Research Program of Zhejiang, China (No. LGF21H080003); and the Zhejiang Medical Association Clinical Medical Research special fund project (No. 2022ZYC-D09).
Thrombotic Prediction Model Based on Epigenetic Regulator Mutations in Essential Thrombocythemia Patients Using Survival Analysis in Recurrent Events

Pirun Saelue,Patuma Sinthujaroen,Supaporn Suwiwat,Paramee Thongsuksai

DOI: https://doi.org/10.1177/10760296241263099

2024-07-27

Clinical and Applied Thrombosis/Hemostasis

Abstract:Clinical and Applied Thrombosis/Hemostasis, Volume 30, Issue , January-December 2024. IntroductionEssential thrombocythemia (ET) involves the proliferation of megakaryocytes and platelets and is associated with an increased risk of thrombosis. We aimed to evaluate thrombotic risks in patients with epigenetic regulator mutations and generate a model to predict thrombosis in ET.Materials and MethodsThis cohort study enrolled patients aged > 15 years diagnosed with ET at the Songklanakarind Hospital between January 2002 and December 2019. Twenty-five targeted gene mutations, including somatic driver mutations (JAK2, CALR, MPL), epigenetic regulator mutations (TET2, DNMT3A, IDH1, IDH2, TET2, ASXL1, EZH2, SF3B1, SRSF2) and other genes relevant to myeloid neoplasms, were identified using next-generation sequencing. Thrombotic events were confirmed based on clinical condition and imaging findings, and thrombotic risks were analyzed using five survival models with the recurrent event method.ResultsNinety-six patients were enrolled with a median follow-up of 6.91 years. Of these, 15 patients experienced 17 arterial thrombotic events in total. Patients with JAK2 mutation and IDH1 mutation had the highest frequency of thrombotic events with somatic driver mutations (17.3%) and epigenetic regulator mutations (100%). The 10-year thrombosis-free survival rate was 81.3% (95% confidence interval: 72.0-91.8%). IDH1 mutation was a significant factor for thrombotic risk in the multivariate analysis for all models. The Prentice, William, and Peterson (PWP) gap-time model was the most appropriate prediction model.ConclusionsThe PWP gap-time model was a good predictive model for thrombotic risk in patients with ET. IDH1 mutation was significant risk factors for thrombosis; however, further studies with a larger sample size should confirm this and provide more insight.

peripheral vascular disease,hematology
Personalized management of essential thrombocythemia—application of recent evidence to clinical practice

A Tefferi,T Barbui

DOI: https://doi.org/10.1038/leu.2013.99

2013-04-05

Leukemia

Abstract:The World Health Organization (WHO) classification system has recently strengthened the diagnostic criteria for essential thrombocythemia (ET) by lowering the threshold platelet count, underscoring its morphological distinction from early/prefibrotic myelofibrosis (MF) and incorporating molecular markers of clonality. The International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) examined the clinical relevance of this process in 1104 cases of locally diagnosed ‘ET’ and showed worse overall, leukemia-free and fibrosis-free survival, and a higher risk of bleeding in early/prefibrotic MF (n=180) vs WHO-defined ET (n=891). The risk of thrombosis was similar between the two entities and, in WHO-defined ET, was predicted by thrombosis history, older age, cardiovascular risk factors and JAK2V617F. A prognostic model based on these risk factors identified patient groups in ET with residual risk of thrombosis, despite treatment with conventional therapy. The main objectives of the current perspective are to underscore the prognostic importance of morphological confirmation in the diagnosis of ET and provide management recommendations, in both WHO-defined ET and early/prefibrotic MF, based on observations from the aforementioned IWG-MRT and other studies. In so doing, we are fully cognizant and sympathetic of the fact that some of our recommendations need to be tested in prospective controlled studies.

oncology,hematology
The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia

Luca Tosoni,Gian Luca Morelli,Gaia Tomadini,Davide Lazzarotto,Carla Filì,Erica Simeone,Maria Elena Zannier,Chiara Callegari,Matteo Fanin,Giulia Battaglia,Melissa Bergnach,Daniela Damiani,Renato Fanin,Mario Tiribelli

DOI: https://doi.org/10.1038/s41408-024-01151-2

IF: 9.812

2024-10-02

Blood Cancer Journal

Abstract:Blood Cancer Journal, Published online: 01 October 2024; doi:10.1038/s41408-024-01151-2 The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia

oncology,hematology
Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma

Abolfazl Razzaghdoust,Bahram Mofid,Masoumeh Zangeneh

DOI: https://doi.org/10.1177/1078155219861423

2019-07-18

Journal of Oncology Pharmacy Practice

Abstract:Purpose Chemotherapy-induced thrombocytopenia is a serious complication in chemotherapy-treated patients. Identification of patients at risk for chemotherapy-induced thrombocytopenia could have clinical value in personalized management of patients and optimized administration of prophylactic thrombopoietic agents. The aim of this study was to develop a predictive model for chemotherapy-induced thrombocytopenia (platelet count < 100,000/μl) in cancer patients undergoing chemotherapy. Methods A total of 14 covariates were prospectively assessed as explanatory variables in a cohort of consecutive patients with solid tumors or lymphoma. A multivariable logistic regression model was developed after univariable analysis. A bootstrapping technique was applied for internal validation. Results Data from 305 patients during 1732 chemotherapy cycles were considered for analysis. Forty-eight patients (15.73%) developed chemotherapy-induced thrombocytopenia during their treatment course. The multivariable model exhibited three final predictors for chemotherapy-induced thrombocytopenia, including high ferritin (odds ratio, 4.41; bootstrap P = 0.001), estimated glomerular filtration rate <60 ml/min/1.73 m 2 (odds ratio, 3.08; bootstrap P = 0.005), and body mass index <23 kg/m 2 (odds ratio, 2.23; bootstrap P = 0.044). The main characteristics of the model include sensitivity 75%, specificity 65.4%, positive likelihood ratio 2.16, and negative likelihood ratio 0.382. Moreover, the model was well calibrated (Hosmer–Lemeshow P = 0.713) and the area under the receiver operating characteristic curve was 0.735 (95% confidence interval, 0.654–0.816; P < 0.001). Conclusions We developed a predictive model for chemotherapy-induced thrombocytopenia based on readily available and easily assessable clinical and laboratory factors. This study may provide a valuable insight to guide optimized treatment of cancer patients. Further studies with larger sample size are warranted.

oncology,pharmacology & pharmacy
One thousand patients with essential thrombocythemia: the Mayo Clinic experience

Naseema Gangat,Omer Karrar,Aref Al-Kali,Kebede H. Begna,Michelle A. Elliott,Alexandra P. Wolanskyj-Spinner,Animesh Pardanani,Curtis A. Hanson,Rhett P. Ketterling,Ayalew Tefferi

DOI: https://doi.org/10.1038/s41408-023-00972-x

IF: 9.812

2024-01-19

Blood Cancer Journal

Abstract:We describe 1000 patients with essential thrombocythemia seen at the Mayo Clinic between 1967 and 2023: median age 58 years (18–90), females 63%, JAK2 / CALR / MPL -mutated 62%/27%/3%, triple-negative (TN) 8%, extreme thrombocytosis (ExT; platelets ≥1000 × 10 9 /L) 26%, leukocytosis (leukocyte count >11 × 10 9 /L) 20%, and abnormal karyotype 6%. JAK2 -mutated patients were older (median 71 years), and CALR mutated (52 years), and TN (50 years) younger ( p < 0.01). Female gender clustered with TN (73%) and JAK2 (69%) vs. CALR / MPL (49%/47%) mutations ( p < 0.01). ExT clustered with CALR (type-2 more than type-1) and TN and leukocytosis with JAK2 mutation ( p < 0.01). In multivariable analysis, risk factors for overall survival were older age ( p < 0.01), male gender (HR 1.8), absolute neutrophil count (ANC) ≥ 8 × 10 9 /L (HR 1.6), absolute lymphocyte count (ALC) < 1.7 × 10 9 /L (HR 1.5), hypertension (HR 1.7), and arterial thrombosis history (HR 1.7); for leukemia-free survival, ExT (HR 2.3) and abnormal karyotype (HR 3.1); for myelofibrosis-free survival, ANC ≥ 8 × 10 9 /L (HR 2.3) and MPL mutation (HR 3.9); for arterial thrombosis-free survival, age ≥60 years (HR 1.9), male gender (HR 1.6), arterial thrombosis history (HR 1.7), hypertension (HR 1.7), and JAK2 mutation (HR 1.8); for venous thrombosis-free survival, male gender (HR 1.8) and venous thrombosis history (HR 3.0). Associations between ExT and leukemic transformation and between ANC and fibrotic progression were limited to JAK2 -mutated cases. Aspirin therapy appeared to mitigate both arterial (HR 0.4) and venous (HR 0.4) thrombosis risk. HR-based risk models delineated patients with median survivals ranging from 10 years to not reached and 20-year leukemia/myelofibrosis incidences from 3%/21% to 12.8%/49%. The current study provides both novel and confirmatory observations of essential thrombocythemia.

oncology,hematology
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience

Giuseppe G. Loscocco,Francesca Gesullo,Giulio Capecchi,Alessandro Atanasio,Chiara Maccari,Francesco Mannelli,Alessandro M. Vannucchi,Paola Guglielmelli

DOI: https://doi.org/10.1038/s41408-023-00968-7

IF: 9.812

2024-01-19

Blood Cancer Journal

Abstract:We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 and 2023: median age 59 years (18–95), females 65%, JAK2 / CALR / MPL -mutated 66%/19%/4%, triple-negative (TN) 11%. Extreme thrombocytosis (ExT, platelets ≥1000 × 10 9 /L) in 16%, leukocytosis (leukocytes >11 × 10 9 /L) in 16%, and at least one cardiovascular risk factor in 52% of cases. JAK2 -mutated patients were older (median 62 years) and CALR -mutated and TN (53 years for both) younger ( p < 0.001). Female gender clustered with TN (76%) and JAK2 (67%) vs CALR (46%) mutations ( p < 0.001). ExT clustered with CALR (type-2 more than type-1), TN and MPL , and leukocytosis with JAK2 mutation ( p < 0.001). In multivariable analysis, risk factors for arterial thrombosis-free survival were age ≥60 years (HR 2.0; p < 0.001) and JAK2 mutation (HR 1.3; p = 0.02) with borderline significance for male gender ( p = 0.08) and cardiovascular risk factors ( p = 0.08); for venous thrombosis-free survival, JAK2 mutation (HR 1.9; p = 0.03) with borderline significance for venous thrombosis history ( p = 0.07); for overall survival, older age ( p < 0.001), male gender (HR 1.9; p < 0.001), absolute neutrophil count (ANC) ≥ 8 × 10 9 /L (HR 1.8; p = 0.01), absolute lymphocyte count (ALC) < 1.7 × 10 9 /L (HR 1.2; p = 0.03); for myelofibrosis-free survival, CALR mutation (HR 2.7; p < 0.001, particularly for CALR type 1/1-like, HR 3.3) and MPL mutation (HR 3.9; p = 0.001); for leukemia-free survival, older age ( p = 0.03). Cytoreductive therapy appeared to mitigate both venous (HR 0.3; p = 0.01) and arterial thrombosis (HR 4; p = 0.04); there was a trend for aspirin in preventing arterial thrombosis recurrence. The current study provides real-world observations in essential thrombocythemia, representing a valid source document for interpreting current literature and planning future studies.

oncology,hematology
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management

Ayalew Tefferi,Alessandro Maria Vannucchi,Tiziano Barbui

DOI: https://doi.org/10.1002/ajh.27216

IF: 13.265

2024-01-27

American Journal of Hematology

Abstract:Overview Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation‐prevalent myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might be interrupted by thrombotic or hemorrhagic complications, microcirculatory symptoms (e.g., headaches, lightheadedness, and acral paresthesias), and, less frequently, by disease transformation into myelofibrosis (MF) or acute myeloid leukemia. Diagnosis In addition to thrombocytosis (platelets ≥450 × 109/L), formal diagnosis requires the exclusion of other myeloid neoplasms, including prefibrotic MF, polycythemia vera, chronic myeloid leukemia, and myelodysplastic syndromes with ring sideroblasts and thrombocytosis. Bone marrow morphology typically shows increased number of mature‐appearing megakaryocytes distributed in loose clusters. Genetics: Approximately 80% of patients express myeloproliferative neoplasm driver mutations (JAK2, CALR, MPL), in a mutually exclusive manner; in addition, about 50% harbor other mutations, the most frequent being TET2 (9%–11%), ASXL1 (7%–20%), DNMT3A (7%), and SF3B1 (5%). Abnormal karyotype is seen in 35 years in younger patients. The triple A survival risk model, based on Age, Absolute neutrophil count, and Absolute lymphocyte count, effectively delineates high‐, intermediate‐1‐, intermediate‐2‐, and low‐risk disease with corresponding median survivals of 8, 14, 21, and 47 years. Risk Factors for Thrombosis Four risk categories are considered: very low (age ≤60 years, no thrombosis history, JAK2 wild‐type), low (same as very low but JAK2 mutation present), intermediate (same as low but age >60 years), and high (thrombosis history or age >60 years with JAK2 mutation). Mutations and Prognosis MPL and CALR‐1 mutations have been associated with increased risk of MF transformation; spliceosome with inferior overall and MF‐free survival; TP53 with leukemic transformation, and JAK2V617F with thrombosis. Leukemic transformation rate at 10 years is <1% but might be higher in JAK2‐mutated patients with extreme thrombocytosis and those with abnormal karyotype. Treatment The main goal of therapy is to prevent thrombosis. In this regard, once‐daily low‐dose aspirin is advised for all patients and twice daily for low‐risk disease. Cytoreductive therapy is advised for high‐risk and optional for intermediate‐risk disease. First‐line cytoreductive drugs of choice are hydroxyurea and pegylated interferon‐α and second‐line busulfan. Additional Content The current review includes specific treatment strategies in the context of extreme thrombocytosis, pregnancy, splanchnic vein thrombosis, perioperative care, and post‐essential thrombocythemia MF, as well as new investigational drugs.

hematology
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor model

Stefano Molica,Diana Giannarelli,Andrea Visentin,Gianluigi Reda,Paolo Sportoletti,Anna Maria Frustaci,Annalisa Chiarenza,Stefania Ciolli,Candida Vitale,Luca Laurenti,Lorenzo De Paoli,Roberta Murru,Massimo Gentile,Riccardo Moia,Gian Matteo Rigolin,Luciano Levato,Annamaria Giordano,Giovanni Del Poeta,Caterina Stelitano,Marina Deodato,Claudia Ielo,Alessandro Noto,Valerio Guarente,Marta Coscia,Alessandra Tedeschi,Gianluca Gaidano,Antonio Cuneo,Robin Foa',Livio Trentin,Francesca Romana Mauro

DOI: https://doi.org/10.1002/ajh.26502

IF: 13.265

2022-02-25

American Journal of Hematology

Abstract:Supporting InformationFilenameDescriptionajh26502-sup-0001-Supinfo.docxWord 2007 document , 861.6 KBAppendix S1: Supporting Informationajh26502-sup-0002-Tables.docxWord 2007 document , 25.1 KBAppendix S2: Supplementary TablesPlease note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon

Francisca Ferrer‐Marín,Juan Carlos Hernández‐Boluda,Alberto Alvarez‐Larrán

DOI: https://doi.org/10.1111/bjh.19403

2024-04-10

British Journal of Haematology

Abstract:ET encompasses different genomic entities, each with a distinct clinical course, prognosis and even different response to cytoreductive therapy. In this review, we perform a critical review of risk stratification systems, the evidence for cytoreductive and anti‐platelet treatment, the criteria for switching to a second line and the role of new drugs. Besides evidence‐based management according to revised IPSET‐thrombosis stratification, we also provide specific observations for those patients with CALR‐, MPL‐mutated and triple‐negative ET, as well as cases with high‐risk mutations. Summary Essential thrombocythaemia (ET) is a myeloproliferative neoplasm characterized by an increased risk of vascular complications and a tendency to progress to myelofibrosis and acute leukaemia. ET patients have traditionally been stratified into two thrombosis risk categories based on age older than 60 years and a history of thrombosis. More recently, the revised IPSET‐thrombosis scoring system, which accounts for the increased risk linked to the JAK2 mutation, has been incorporated into most expert recommendations. However, there is increasing evidence that the term ET encompasses different genomic entities, each with a distinct clinical course and prognosis. Moreover, the effectiveness and toxicity of cytoreductive and anti‐platelet treatments differ depending on the molecular genotype. While anti‐platelets and conventional cytoreductive agents, mainly hydroxycarbamide (hydroxyurea), anagrelide and pegylated interferon, remain the cornerstone of treatment, recent research has shed light on the effectiveness of novel therapies that may help improve outcomes. This comprehensive review focuses on the evolving landscape of treatment strategies in ET, with an emphasis on the role of molecular profiling in guiding therapeutic decisions. Besides evidence‐based management according to revised IPSET‐thrombosis stratification, we also provide specific observations for those patients with CALR‐, MPL‐mutated and triple‐negative ET, as well as cases with high‐risk mutations.

hematology
Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study

Shengling Ma,Jennifer La,Kaitlin N. Swinnerton,Danielle Guffey,Raka Bandyo,Giordana De Las Pozas,Katy Hanzelka,Xiangjun Xiao,Cristhiam M. Rojas‐Hernandez,Christopher I. Amos,Vipul Chitalia,Katya Ravid,Kelly W. Merriman,Christopher R. Flowers,Nathanael Fillmore,Ang Li

DOI: https://doi.org/10.1002/ajh.27335

IF: 13.265

2024-04-25

American Journal of Hematology

Abstract:Thrombosis in Lymphoma. Venous thromboembolism (VTE) poses a significant risk to cancer patients receiving systemic therapy. The generalizability of pan‐cancer models to lymphomas is limited. Currently, there are no reliable risk prediction models for thrombosis in patients with lymphoma. Our objective was to create a risk assessment model (RAM) specifically for lymphomas. We performed a retrospective cohort study to develop Fine and Gray sub‐distribution hazard model for VTE and pulmonary embolism (PE)/ lower extremity deep vein thrombosis (LE‐DVT) respectively in adult lymphoma patients from the Veterans Affairs national healthcare system (VA). External validations were performed at the Harris Health System (HHS) and the MD Anderson Cancer Center (MDACC). Time‐dependent c‐statistic and calibration curves were used to assess discrimination and fit. There were 10,313 (VA), 854 (HHS), and 1858 (MDACC) patients in the derivation and validation cohorts with diverse baseline. At 6 months, the VTE incidence was 5.8% (VA), 8.2% (HHS), and 8.8% (MDACC), respectively. The corresponding estimates for PE/LE‐DVT were 3.9% (VA), 4.5% (HHS), and 3.7% (MDACC), respectively. The variables in the final RAM included lymphoma histology, body mass index, therapy type, recent hospitalization, history of VTE, history of paralysis/immobilization, and time to treatment initiation. The RAM had c‐statistics of 0.68 in the derivation and 0.69 and 0.72 in the two external validation cohorts. The two models achieved a clear differentiation in risk stratification in each cohort. Our findings suggest that easy‐to‐implement, clinical‐based model could be used to predict personalized VTE risk for lymphoma patients.

hematology
Machine Learning for Prediction of Cancer-Associated Venous Thromboembolism

Simon Mantha,Andrew Dunbar,Kelly L. Bolton,Sean Devlin,Dmitriy Gorenshteyn,Mark Donoghue,Maria E. Arcila,Gerald A. Soff

DOI: https://doi.org/10.1182/blood-2020-138579

IF: 20.3

2020-11-05

Blood

Abstract:Background: Several clinical prediction scores have been designed to assess the risk of cancer-associated thrombosis (CAT). The most commonly used in current clinical practice is the Khorana score, however it is applicable only to patients prior to initiation of chemotherapy. We now apply machine learning with clinical, demographic, and genomics parameters to predict CAT events. Methods: The random survival forest (RSF) ensemble learning method was selected to illustrate a machine approach to CAT prediction. The cohort consisted of 14,223 individuals with a solid tumor malignancy and MSK IMPACT somatic genomic data collected during the years 2014 to 2016. CAT was defined as the diagnosis of lower extremity deep vein thrombosis (proximal or distal) or pulmonary embolism, incidental or symptomatic. Covariates considered for inclusion in the model consisted of tumor type, metastatic status, age, exposure to cytotoxic chemotherapy in the month before cohort entry, time elapsed since cancer diagnosis, time elapsed since tumor sampling, normalized mean blood cell counts (white cell count, hemoglobin, platelet count) in the prior 3 months, normalized mean prothrombin time (PT) and activated partial thromboplastin time (aPTT) in the prior 3 months, body mass index (BMI), and presence or absence of a somatic genetic alteration for oncogenes/tumor suppressor genes with an alteration frequency ≥ 1.5% (n = 56). The primary endpoint consisted of time to CAT episode. The C-index for models including different covariates was derived from the test holdout sample using repeated 10-fold cross-validation. The C-index, measuring the relative agreement between the RSF predicted risk and the CAT times of patients, has values between 0.5 and 1.0 with the latter indicating perfect agreement. Results: 12,040 patients were included in the final analysis. There were 855 CAT events during the observation period. The most common tumor types were lung (17%), breast (15%) and colorectal cancer (9%). Blood cell count data and coagulation parameters were missing for 8% and 51% of patients respectively. Using cross-validation, the baseline model with cancer type and metastatic status had a C-index of 0.62 (95% CI = 0.61-0.64), which increased to 0.65 (95% CI = 0.63-0.66) with the addition of chemotherapy, age, time from tissue sampling, time from cancer diagnosis and BMI. Further adding genetic data increased the C-index to 0.68 (95% CI = 0.66-0.69). Replacing genetic data in this model with cell counts and coagulation parameters resulted in a C-index of 0.69 (95% CI = 0.68-0.70). The model with all available covariates had a C-index of 0.70 (95% CI = 0.69-0.71). The cumulative incidence of CAT at 6 months for 5 categories of predicted risk using the model with all available covariates is plotted in Figure A. Scaled Ishwaran-Kogalur Variable Importance (VIMP) values, presented in Figure B, indicate that cancer type and prior chemotherapy are the two top factors for model performance. Conclusions: Machine learning is a promising approach in the search of more accurate and generalizable models for prediction of CAT. In the application described here, the use of random survival forests performed well without information about future chemotherapy administration. Additional work is needed to identify the optimal algorithm and covariates, including better delineation of which cancer genomic information should be retained. Future models will have to be validated independently before being used for patient care. Disclosures Mantha: Physicians Education Resource: Honoraria; MJH Associates: Honoraria. Bolton:GRAIL: Research Funding. Soff:Bristol-Myers Squibb, Pfizer: Honoraria; Dova Pharmaceuticals: Honoraria; Janssen Scientific Affairs: Honoraria; Amgen: Research Funding; Janssen Scientific Affairs: Research Funding; Amgen: Honoraria; Dova Pharmaceuticals: Research Funding.

hematology
Retrospective cohort study for thrombocytopenia during concurrent chemoradiotherapy for rectal cancer

Yue Teng,Dapeng Ma,Yan Yan,Jianhao Geng,Zhiyan Liu,Xianggao Zhu,Shuai Li,Yangzi Zhang,Hongzhi Wang,Yong Cai,Haizhen Yue,Yongheng Li,Weihu Wang

DOI: https://doi.org/10.3389/fonc.2023.1289824

IF: 4.7

2024-01-03

Frontiers in Oncology

Abstract:Background: The aim of this article was to establish the clinical prognostic models and identify the predictive radiation dosimetric parameters for thrombocytopenia during concurrent chemoradiotherapy for rectal cancer. Methods: In this retrospective cohort study, patients with rectal adenocarcinoma undergoing concurrent long-term chemoradiotherapy were included. The primary outcome of interest was grade 2 or higher (2+) thrombocytopenia (platelet(PLT) count <75,000/μL). Secondary outcomes included: grade 1 or higher thrombocytopenia (PLT count<100,000/μL) and the PLT count during chemoradiotherapy and its nadir. The risk prediction model was developed by logistic regression to identify clinical predictors of 2+ thrombocytopenia. Univariate linear regression models were used to test correlations between radiation dosimetric parameters and the absolute PLT count at nadirs. Results: This retrospective cohort comprised 238 patients. Fifty-four (22.6%) patients developed thrombocytopenia during concurrent chemoradiotherapy, while 15 (6.3%) patients developed 2+ thrombocytopenia. Four independently associated risk factors, including age, Alb level, PLT count, and chemotherapy regimen, were included in the final model and used to form a 2+ thrombocytopenia probability estimation nomogram. The C‐index was 0.87 (95% CI: 0.78–0.96). The calibration plot showed a moderate agreement, and the Brier score was 0.047 (95% CI: 0.025–0.070). The total absolute volume of bone marrow irradiated by 5 Gy, 10 Gy and 15 Gy of radiation (BM-V 5ab , BM-V 10ab , BM-V 15ab ), calculated by the volume of bone marrow multiplied by the corresponding Vx, were identified as new predictors. The nadir of PLT was found to be negatively correlated with BM-V 5ab (β = -0.062, P =0.030), BM-V 10ab (β = -0.065, P =0.030) and BM-V 15ab (β = -0.064, P =0.042). Conclusion: The occurrence of 2+ thrombocytopenia during concurrent chemoradiotherapy for rectal cancer can be predicted by the patient's baseline status and chemoradiotherapy regimen, and low dose irradiation of bone marrow can affect the level of platelets during the treatment.

oncology
Are thrombosis, progression, and survival in ET predictable?

Ghaith Abu-Zeinah,Katie Erdos,Neville Lee,Ahamed Lebbe,Imane Bouhali,Mohammed Khalid,Richard T. Silver,Joseph M. Scandura

DOI: https://doi.org/10.1038/s41408-024-01079-7

IF: 9.812

2024-06-26

Blood Cancer Journal

Abstract:Blood Cancer Journal, Published online: 25 June 2024; doi:10.1038/s41408-024-01079-7 Are thrombosis, progression, and survival in ET predictable?

oncology,hematology
A Prediction Model for Severe Hematological Toxicity of BTK Inhibitors

Dan Jiang,Zaiwei Song,Peng Liu,Zeyuan Wang,Rongsheng Zhao

DOI: https://doi.org/10.1007/s00277-023-05371-7

2023-01-01

Annals of Hematology

Abstract:Bruton’s tyrosine kinase inhibitor (BTKi) has revolutionized the treatment of B-cell lymphomas. However, BTKi-related hematological toxicity hinders treatment continuity and may further affect clinical efficacy. To identify risk factors and predict the likelihood of BTKi-related hematological toxicities, we constructed and validated a prediction model for severe hematological toxicity of BTKi. Approved by the hospital medical science research ethics committee (No. M2022427), we collected real-world data in patients treated with BTKi from a Lymphoma Research Center in China. The outcome of interest was severe hematological toxicity caused by BTKi. 36 candidate variables were categorized into demographics, diagnostic and treatment information, laboratory data, and medical history. The study sample was randomly divided into training (70
Predicting treatment-free remission outcomes in Chronic Myeloid Leukemia patients using an integrated model of tumor-immune dynamics

Artur C. Fassoni,Ingo Roeder,Ingmar Glauche

DOI: https://doi.org/10.1101/2024.10.10.617526

2024-10-12

Abstract:The interactions between tumor and the immune system are main factors in determining cancer treatment outcomes. In Chronic Myeloid Leukemia (CML), considerable evidence shows that the dynamics between residual leukemia and the patient’s immune system can result in either sustained disease control, leading to treatment-free remission (TFR), or disease recurrence. The question remains how to integrate mechanistic and data-driven models to support prediction of treatment outcomes. Starting from classical ecological modeling concepts, which allow to explicitly account for immune interactions at the cellular level, we incorporate time-course data on natural killer (NK) cell number, function, and their tumor-induced suppression into a model of CML treatment. We identify relevant time scales governing treatment and immune response, enabling refined model calibration using tumor and NK cell time courses from different datasets. While the model successfully describes patient-specific response dynamics, critical parameters for predicting treatment outcome remain uncertain. However, by explicitly incorporating tumor load changes in response to TKI dose alterations, these parameters can be estimated and used to derive model predictions for treatment cessation. Further exploring dynamic changes in the number of functional immune cells, we suggest specific measurement strategies of immune effector cell populations to enhance prediction accuracy for CML recurrence following treatment cessation. The generalizability and flexibility of our approach represent a significant step towards quantitative, personalized medicine that integrates tumor-immune dynamics to guide clinical decisions and optimize dynamic cancer therapies.

Systems Biology
Therapeutic Strategies and Predictive Models for Xp11.2 Translocation/tfe3 Gene Fusion Renal Cell Carcinoma in Adults Based on Data of Two Chinese Medical Centers.

Yunkai Yang,Changfeng Zhao,Zhida Wang,Feng Liu,Ming Zhao,Huiwen Yang,Jun Chen,Xuejing Chen,Min Shi,Dixing Jiang,Xiaoting Luo,Yue Duan,Yuchen Bai

DOI: https://doi.org/10.18632/aging.205452

2024-01-01

Abstract:OBJECTIVE:This study aims to establish an effective predictive model for predicting Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma (TFE3-RCC) and develop optimal therapeutic strategies. METHODS:Data from 4961 patients diagnosed with renal cell carcinoma at two medical centers in China were retrospectively analyzed. A cohort of 1571 patients from Zhejiang Provincial People's Hospital (Ra cohort) was selected to construct the model. Another cohort of 1124 patients from the Second Affiliated Hospital of Zhejiang Chinese Medical University was used for external validation (the Ha cohort). All patients with TFE3-RCC in both cohorts were included in the Ta cohort for the prognostic analysis. Univariate and multivariate binary logistic regression analyses were performed to identify independent predictors of the predictive nomogram. The apparent performance of the model was validated. Decision curve analysis was also performed to assess the clinical utility of the developed model. Factors associated with progression and prognosis in the Ta cohort were analyzed using the log-rank method, and Cox regression analysis and Kaplan-Meier survival curves were used to describe the effects of factors on prognosis and progression. RESULTS:Univariate and multivariate logistic regression analyses demonstrated that age, sex, BMI, smoking, eosinophils, and LDL were independent predictors of TFE3-RCC. Therefore, a predictive nomogram for TFE3-RCC, which had good discriminatory power (AUC = 0.796), was constructed. External validation (AUC = 0.806) also revealed good predictive ability. The calibration curves displayed good consistency between the predicted and observed incidences of TFE3-RCC. Invasion of regional lymph nodes, tyrosine kinase inhibitors, and surgical methods were independent factors associated with progression. Tyrosine kinase inhibitors are independent prognostic factors. CONCLUSION:This study not only proposed a high-precision clinical prediction model composed of various variables for the early diagnosis of Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma but also optimized therapeutic strategies through prognostic analysis.
A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy

Xiaoshuai Zhang,Bingcheng Liu,Jian Huang,Yanli li Zhang,Na Xu,Robert Peter Gale,Weiming Li,Xiaoli Liu,Huanling Zhu,Ling Pan,Yunfan Yang,Hai Lin,Xin Du,Rong Liang,Chunyan Chen,Xiaodong Wang,Guohui Li,Zhougang Liu,Yanqing Zhang,Zhenfang Liu,Jianda Hu,Chunshui Liu,Fei Li,Wei Yang,Li Meng,Yanqiu Han,Li'e Lin,Zhenyu Zhao,Chuanqing Tu,Caifeng Zheng,Yanliang Bai,Zeping Zhou,Suning Chen,Huiying Qiu,Lijie Yang,Xiuli Sun,Hui Sun,Li Zhou,Zelin Liu,Danyu Wang,Jianxin Guo,Liping Pang,Qingshu Zeng,Xiaohui Suo,Weihua Zhang,Yuanjun Zheng,Xiaojun Huang,Qian Jiang

DOI: https://doi.org/10.1182/blood.2024024761

IF: 20.3

2024-07-25

Blood

Abstract:Although tyrosine kinase inhibitor (TKI) therapy has markedly improved the survival of people with chronic-phase chronic myeloid leukemia (CML), 20-30% of people still experienced therapy failure. Data from 1,955 consecutive subjects with chronic-phase CML diagnosed by the European LeukemiaNet (ELN) recommendations from 1 center receiving initial TKI imatinib or a second-generation (2G-) TKI therapy were interrogated to develop a clinical prediction model for TKI therapy failure. This model was...

hematology
Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis in Cancer Patients.

Binliang Liu,Junying Xie,Xiaoying Sun,Yanfeng Wang,Zhong Yuan,Xiyu Liu,Zhou Huang,Jiani Wang,Hongnan Mo,Zongbi Yi,Xiuwen Guan,Lixi Li,Wenna Wang,Hong Li,Fei Ma,Yi-Xin Zeng

DOI: https://doi.org/10.3389/fcvm.2020.571227

IF: 3.6

2020-01-01

Frontiers in Cardiovascular Medicine

Abstract:e14031 Background: The central venous catheter brings convenience for drug delivery and improves comfort for cancer patients, it also causes serious complications. The most common one is catheter-related thrombosis (CRT). This study aimed to evaluate the incidence and risk factors of CRT in cancer patients, and to develop an effective prediction model for CRT in cancer patients. Methods: The development of our prediction model was based on the data of a retrospective cohort (n = 3131) from National Cancer Center. The validation of our prediction model was done in a prospective cohort from National Cancer Center (n = 685) and a retrospective cohort from Hunan Cancer Hospital (n = 61). The predictive accuracy and the discriminative ability were determined by the receiver operating characteristic curves and calibration plots. Results: Multivariate analysis demonstrated that sex, cancer type, catheter type, position of the catheter tip, chemotherapy status, and antiplatelet/anticoagulation status at baseline were independent risk factors for CRT. The area under receiver operating characteristic (ROC) curve of our prediction model was 0.741 (CI: 0.715-0.766) in the primary cohort; 0.754 (CI: 0.704-0.803) and 0.658 (CI: 0.470-0.845) in validation cohorts respectively. Good calibration and clinical impact were also shown in primary and validation cohorts. The high-risk group had a higher incidence of CRTs than the low-risk group in the primary cohort and two validation cohort (p < 0.001). Conclusions: Our model is a novel prediction tool for CRT risk which helps to assigning cancer patients into high-risk or low-risk group accurately. Our model will be valuable for clinicians in decision making of thromboprophylaxis.
Risk of Recurrent Venous Thromboembolism in Patients with Cancer: An Individual Patient Data Meta-analysis and Development of a Prediction Model

Vincent R. Lanting,Toshihiko Takada,Floris T. M. Bosch,Andrea Marshall,Michael A. Grosso,Annie M. Young,Agnes Y. Y. Lee,Marcello Di Nisio,Gary E. Raskob,Pieter W. Kamphuisen,Harry R. Büller,Nick van Es

DOI: https://doi.org/10.1055/a-2418-3960

2024-10-18

Thrombosis and Haemostasis

Abstract:Background About 7% of patients with cancer-associated venous thromboembolism (CAT) develop a recurrence during anticoagulant treatment. Identification of high-risk patients may help guide treatment decisions. Aim To identify clinical predictors and develop a prediction model for on-treatment recurrent CAT. Methods For this individual patient data meta-analysis, we used data from four randomized controlled trials evaluating low-molecular-weight heparin or direct oral anticoagulants (DOACs) for CAT (Hokusai VTE Cancer, SELECT-D, CLOT, and CATCH). The primary outcome was adjudicated on-treatment recurrent CAT during a 6-month follow-up. A clinical prediction model was developed using multivariable logistic regression analysis with backward selection. This model was validated using internal–external cross-validation. Performance was assessed by the c-statistic and a calibration plot. Results After excluding patients using vitamin K antagonists, the combined dataset comprised 2,245 patients with cancer and acute CAT who were treated with edoxaban (23%), rivaroxaban (9%), dalteparin (47%), or tinzaparin (20%). Recurrent on-treatment CAT during the 6-month follow-up occurred in 150 (6.7%) patients. Predictors included in the final model were age (restricted cubic spline), breast cancer (odds ratio [OR]: 0.42; 95% confidence interval [CI]: 0.20–0.87), metastatic disease (OR: 1.44; 95% CI: 1.01–2.05), treatment with DOAC (OR: 0.66; 95% CI: 0.44–0.98), and deep vein thrombosis only as an index event (OR: 1.72; 95% CI: 1.31–2.27). The c-statistic of the model was 0.63 (95% CI: 0.54–0.72) after internal–external cross-validation. Calibration varied across studies. Conclusion The prediction model for recurrent CAT included five clinical predictors and has only modest discrimination. Prediction of recurrent CAT at the initiation of anticoagulation remains challenging. All authors contributed to the interpretation of the results and writing the manuscript. V.R.L. performed data management, analysis, and led writing of the manuscript. T.T. and N.v.E. performed analysis. F.T.M.B. has written the study protocol and obtained the datasets. Received: 17 July 2024 Accepted: 09 September 2024 Accepted Manuscript online: 19 September 2024 Article published online: 16 October 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Stuttgart · New York

peripheral vascular disease,hematology

Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients

Development and validation of a model for the early prediction of progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: a multicentre retrospective study

Thrombotic Prediction Model Based on Epigenetic Regulator Mutations in Essential Thrombocythemia Patients Using Survival Analysis in Recurrent Events

Personalized management of essential thrombocythemia—application of recent evidence to clinical practice

The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia

Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma

One thousand patients with essential thrombocythemia: the Mayo Clinic experience

One thousand patients with essential thrombocythemia: the Florence-CRIMM experience

Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management

Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor model

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon

Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study

Machine Learning for Prediction of Cancer-Associated Venous Thromboembolism

Retrospective cohort study for thrombocytopenia during concurrent chemoradiotherapy for rectal cancer

Are thrombosis, progression, and survival in ET predictable?

A Prediction Model for Severe Hematological Toxicity of BTK Inhibitors

Predicting treatment-free remission outcomes in Chronic Myeloid Leukemia patients using an integrated model of tumor-immune dynamics

Therapeutic Strategies and Predictive Models for Xp11.2 Translocation/tfe3 Gene Fusion Renal Cell Carcinoma in Adults Based on Data of Two Chinese Medical Centers.

A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy

Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis in Cancer Patients.

Risk of Recurrent Venous Thromboembolism in Patients with Cancer: An Individual Patient Data Meta-analysis and Development of a Prediction Model